Phase 3 Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older
- People who needed a breathing machine (mechanical ventilator) and/or heart/blood pressure support medications for more than 24 hours during their ICU stay
- People whose doctor has decided they are ready to leave the ICU
- People who have signed the informed consent form agreeing to take part
- People whose blood test results show certain markers of heart or kidney stress — specifically, elevated heart stress proteins (NT-proBNP above 800 ng/L or BNP above 90 ng/L) and/or a kidney filtering rate (eGFR) between 25 and 90 ml/min/1.73m² at the time of joining the trial
Who may not be able to join:
- People who are pregnant
- Women who could become pregnant and who do not agree to use an effective form of contraception throughout the study and until the relevant treatment has left the body (confirm with trial site for the full list of accepted contraception methods)
- People who are breastfeeding
- People with a known allergy to the study drug (dapagliflozin) or any of its ingredients
- People who were already taking dapagliflozin before their ICU admission
- People with severe liver scarring/failure (classified as Child-Pugh C)
- People who had or developed a urinary tract infection or a perineal (groin/genital area) infection during their ICU stay, or who have a skin wound near that area (such as a pressure sore near the tailbone) that raises the risk of infection
- People whose kidney filtering rate (eGFR) is below 25 ml/min/1.73m²
- People for whom international medical guidelines already strongly recommend dapagliflozin as a standard treatment — this includes certain people with type 2 diabetes not well controlled by current treatment, people with symptomatic chronic heart failure, or people with chronic kidney disease meeting specific criteria who have been on certain blood pressure medications for at least 4 weeks (confirm with trial site)
- People who do not have national health insurance, or who receive state medical aid (AME)
- People whose freedom is restricted by a court or administrative order
- People currently taking part in another interventional clinical trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Alexandre Mebazaa, MD-PHD, APHP
Phone: 0142499570
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
All-cause mortality; Unscheduled hospital hospitalization for heart failure; Decrease of eGFR by more than 50% from ICU discharge and/or end stage kidney disease defined as an eGFR<15ml/min/1.73m² and/or initiation of renal replacement therapy and/or kidney transplantation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.